Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.885 -0.125 (-1.78%)
Streaming Delayed Price Updated: 3:50 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Receives New Patent for Tenapanor
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance ↗
Via Stocktwits
Ardelyx Stock Slips After-Hours As $100M Shelf Filing Sparks Dilution Fears After Strong Q3 ↗
Via Stocktwits
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗
The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue. 
Via Stocktwits
News headline image
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
4 Analysts Assess Ardelyx: What You Need To Know ↗
 
Via Benzinga
News headline image
Ardelyx (ARDX) Q3 2025 Earnings Call Transcript ↗
Ardelyx (ARDX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake? ↗
The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock. 
Via The Motley Fool
News headline image
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cloudflare Posts Upbeat Q3 Results, Joins Amazon, Roku, Coinbase, Atlassian And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Discover the top movers in Friday's pre-market session. ↗
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Ardelyx Inc (NASDAQ:ARDX) Stock Surges on Q3 2025 Revenue Beat and Raised Guidance ↗
Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.